Optime Care president and CEO Donovan Quill’s byline featured in Today’s Geriatric Medicine on January 4, 2021: “Patient-First Model Meets Needs of Seniors with Rare and Orphan Diseases: Optimizes Personalized Medicine Data, Informs Health Care Decisions, Enhances Population Health Management”
America’s aging population faces unprecedented challenges–both clinical and non-clinical issues–at a time when the senior population is booming and the nation has seen a dramatic shift to home-based care.
To treat this targeted population, industry experts state that orphan drugs will be a major trend to watch in the years ahead, accounting for almost 40% of Food and Drug Administration approvals this year.
But these drugs can be expensive, costing on average $147,000 or more per year. Personalized or precision medicine—a disease treatment and prevention approach that takes into account individual variability in genes, environment and lifestyle for each person—is emerging as a trend for population health management.
A patient-first approach to treating patients with rare and orphan diseases can ensure care continuity across the entire patient journey with robust communication to yield rich data that clinicians can use to make more informed decisions and improve the overall patient experience.
